Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 29.92% | Hold | 3,990,000 | $44.96 | $179M | — | — |
| TGTX - Tg Therapeutics | 8.89% | Hold | 2,280,000 | $23.39 | $53M | — | — |
| OCUL - Ocular Therapeutix | 7.29% | Reduce −5.3% | 5,025,000 | $8.70 | $44M | −282,500 | +$7M |
| ARVN - Arvinas | 5.16% | Add +126.1% | 1,255,000 | $24.63 | $31M | +700,000 | +$16M |
| CDXS - Codexis | 4.51% | Add +153.8% | 8,770,000 | $3.08 | $27M | +5,315,000 | +$16M |
| RYTM - Rhythm Pharmaceuticals | 4.37% | Reduce −2.9% | 500,000 | $52.39 | $26M | −15,000 | +$5M |
| Keros Therapeutics | 3.83% | Add +7.6% | 395,276 | $58.07 | $23M | +27,776 | +$6M |
| Immunome | 3.02% | Add +12.2% | 1,237,500 | $14.62 | $18M | +135,000 | +$5M |
| LQDA - Liquidia | 2.83% | Add +422.5% | 1,698,142 | $10.00 | $17M | +1,373,142 | +$13M |
| ETON - Eton Pharmaceuticals | 2.78% | Add +16.1% | 2,780,000 | $6.00 | $17M | +385,000 | +$9M |
| EWTX - Edgewise Therapeutics | 2.33% | Reduce −9.9% | 522,500 | $26.69 | $14M | −57,500 | +$4M |
| Cargo Therapeutics | 1.97% | Reduce −2.6% | 541,437 | $21.86 | $12M | −14,263 | +$3M |
| APLT - Applied Therapeutics ' | 1.87% | Reduce −21.4% | 1,320,000 | $8.50 | $11M | −360,000 | +$3M |
| PCVX - Vaxcyte | 1.62% | Hold | 85,000 | $114.27 | $10M | — | — |
| NRIX - Nurix Therapeutics | 1.57% | Add +0.3% | 420,000 | $22.47 | $9M | +1,072 | +$694K |
| Acelyrin | 1.56% | Add +19.9% | 1,893,660 | $4.93 | $9M | +313,660 | +$2M |
| TRVI - Trevi Therapeutics | 1.43% | Reduce −2.9% | 2,567,990 | $3.34 | $9M | −77,010 | +$695K |
| Biodesix | 1.16% | Reduce −5.1% | 3,815,000 | $1.83 | $7M | −205,000 | +$820K |
| DNA - Ginkgo Bioworks · CLASS A | 1.11% | New | 820,202 | $8.15 | $7M | +820,202 | +$7M |
| Jasper Therapeutics | 1.11% | Reduce −9.8% | 353,500 | $18.81 | $7M | −38,500 | −$2M |
| XOMA - XOMA Del | 1.10% | Hold | 250,000 | $26.48 | $7M | — | — |
| NUVL - Nuvalent | 1.09% | Add +7.9% | 64,000 | $102.30 | $7M | +4,700 | +$2M |
| NAMS - Newamsterdam Pharma | 0.93% | Add +6.3% | 335,000 | $16.60 | $6M | +20,000 | −$490K |
| URGN - Urogen Pharma | 0.86% | Reduce −1.9% | 404,100 | $12.70 | $5M | −7,900 | −$2M |
| PTGX - Protagonist Therapeutics | 0.79% | Hold | 105,000 | $45.00 | $5M | — | — |
| CYTK - Cytokinetics | 0.66% | Reduce −62.1% | 75,300 | $52.80 | $4M | −123,200 | −$7M |
| Gossamer Bio | 0.62% | Reduce −6.3% | 3,665,010 | $1.01 | $4M | −244,990 | +$183K |
| ZNTL - Zentalis Pharmaceuticals | 0.59% | New | 967,000 | $3.68 | $4M | +967,000 | +$4M |
| Protara Therapeutics | 0.51% | Reduce −27.0% | 1,681,154 | $1.83 | $3M | −623,108 | −$2M |
| RZLT - Rezolute | 0.38% | New | 466,563 | $4.85 | $2M | +466,563 | +$2M |
| Catalyst Pharmaceuticals | 0.37% | Reduce −82.4% | 112,500 | $19.88 | $2M | −527,500 | −$8M |
| ABCL - Abcellera Biologics | 0.35% | Add +300.0% | 800,000 | $2.60 | $2M | +600,000 | +$1M |
| Lyell Immunopharma | 0.32% | Reduce −16.5% | 1,395,000 | $1.38 | $2M | −275,000 | −$496K |
| Allakos | 0.26% | Reduce −13.4% | 2,407,600 | $0.6532 | $2M | −372,400 | −$1M |
| RLMD - Relmada Therapeutics | 0.26% | Reduce −20.0% | 480,000 | $3.24 | $2M | −120,000 | −$245K |
| PEPG - Pepgen | 0.26% | New | 179,200 | $8.55 | $2M | +179,200 | +$2M |
| Revance Therapeutics | 0.24% | New | 275,000 | $5.19 | $1M | +275,000 | +$1M |
| Syros Pharmaceuticals | 0.23% | Reduce −24.3% | 654,943 | $2.15 | $1M | −210,500 | −$3M |
| Aerovate Therapeutics | 0.15% | Hold | 440,000 | $2.09 | $920K | — | — |
| Regulus Therapeutics | 0.14% | Reduce −63.7% | 535,000 | $1.57 | $840K | −940,000 | −$2M |
| IBIO — | 0.14% | Hold | 375,000 | $2.22 | $833K | — | — |
| ADGM - Adagio Med | 0.05% | New | 110,571 | $2.58 | $285K | +110,571 | +$285K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| FDMT - 4D Molecular Therapeutics | 1.66% | Exit | 0 | $20.99 | $7M | −345,750 | −$7M |
| IOVA - Iovance Biotherapeutics | 1.64% | Exit | 0 | $8.02 | $7M | −897,000 | −$7M |
| INTC - Intellia Therapeutics | 1.11% | Exit | 0 | $22.38 | $5M | −218,000 | −$5M |
| Lexicon Pharmaceuticals | 0.72% | Exit | 0 | $1.68 | $3M | −1,875,000 | −$3M |
| Savara | 0.66% | Exit | 0 | $4.03 | $3M | −714,960 | −$3M |
| Ventyx Biosciences | 0.63% | Exit | 0 | $2.31 | $3M | −1,190,000 | −$3M |
| VSTM - Verastem | 0.62% | Exit | 0 | $2.98 | $3M | −915,000 | −$3M |
| FULC - Fulcrum Therapeutics | 0.40% | Exit | 0 | $6.20 | $2M | −285,000 | −$2M |
| Karyopharm Therapeutics | 0.28% | Exit | 0 | $0.8674 | $1M | −1,425,000 | −$1M |
| Pmv Pharmaceuticals | 0.18% | Exit | 0 | $1.62 | $770K | −475,000 | −$770K |
| DSGN - Design Therapeutics | 0.16% | Exit | 0 | $3.35 | $687K | −205,000 | −$687K |
| Aligos Therapeutics | 0.10% | Exit | 0 | $0.3500 | $441K | −1,260,000 | −$441K |
| Reneo Pharmaceuticals | 0.06% | Exit | 0 | $1.51 | $249K | −165,000 | −$249K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2